Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 d
Signs and symptoms include: Generalized urticaria (hives) or widespread pruritic rash Angioedema affecting the face, lips, tongue, or throat Respiratory symptoms including wheezing, dyspnea, or throat tightness Gastrointestinal symptoms such as severe abdominal cramping, nausea, or vomiting (distinct from common GI side effects) Cardiovascular manifestations including tachycardia, hypotension, or dizziness Anaphylaxis represents the most severe form of allergic reaction and constitutes a medical emergency
10.1111/dom.13353 [DOI] [PMC free article] [PubMed] [Google Scholar] 184.van Bloemendaal L, Ten Kulve JS, la Fleur SE, Ijzerman RG, Diamant M
A.Bezares-CaldernL
doi: 10.1007/s10803-015-2655-7 179 WangS
Ginsenoside Rg1 ameliorated experimental colitis by regulating the balance of M1/M2 macrophage polarization and the homeostasis of intestinal flora
